BOSTON and NEW YORK, April 27, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that a conference call will be held on Monday, May 4th, 2015 at 8:00 a.m. ET to discuss financial results for the first quarter 2015 and provide an update on the Auryxia™ (ferric citrate) launch.
In order to participate in the conference call, please call 1-(888) 396-2320 (U.S.), 1-(774) 264-7560 (outside the U.S.), call-in ID: KERYX. The call will also be webcast with slides and accessible through the Investors section of the company’s website at www.keryx.com. The audio replay will be available at http://www.keryx.com, for a period of 15 days after the call.
Keryx will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail: amy.sullivan@keryx.com
Help employers find you! Check out all the jobs and post your resume.
